hec cj pharm (01558.HK) announced that it has reached a cooperation agreement with 3sbio (01530.HK) subsidiary Shenyang 3sbio. According to this agreement, Shenyang 3sbio has obtained the exclusive commercialization rights of benzenesulfonate cellectis in China for specific indications, and will pay the down payment and corresponding research and sales milestone payments to the parent company of hec CJ Pharm, Guangdong HEC Technology Holding.
東陽光藥(01558.HK)與三生製藥(01530.HK)附屬達成合作協議
guangdong hec technology holding (01558.HK) reached a cooperation agreement with 3sbio (01530.HK) and its subsidiary.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated